RNA Sequencing (RNA-seq) for Biomarker Discovery Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

To enable innovative Immune Biomarker Discovery for immune monitoring, Creative Biolabs has established a powerful Immune Monitoring Platform to offer highly customized solutions. RNA sequencing (RNA-seq) is one of our comprehensive strategies for biomarker discovery. In cancer progression, the expression level of relevant genes will change significantly in tumors compared to their healthy counterparts. Therefore, the discovery of specific genes serving as biomarkers is of practical significance for diagnosis and prognosis. RNA-seq provides unprecedented resources and opportunities for cancer biomarker discovery. Creative Biolabs is well equipped and versed in RNA-seq technology. We continue to serve our global clients with professionalism and expertise in employing RNA-seq for immune biomarker discovery.

Background of RNA-seq for Biomarker Discovery

Promising novel biomarkers for the early diagnosis and prognosis of diverse diseases, especially cancers, are urgently required. Transcriptomics is an evolving and continually growing field for biomarker discovery. Biomarker discovery by differentially expressed genes is an important task to characterize the transcriptomics data. The advancement of next-generation sequencing technology (NGS) makes RNA-seq possible. RNA-seq is an important branch of transcriptomics for the identification of novel genes. This technique helps to identify the differentially expressed genes, which are potential biomarker candidates, from the big transcriptomic data. Identification of disease biomarkers by RNA-seq is important in the diagnosis of the different types and subtypes of diseases, with several implications in terms of prognosis and therapy.

RNA-seq for Biomarker Discovery Service at Creative Biolabs

Scientists at Creative Biolabs have performed many RNA-seq analysis projects during the past few years. Many years of experience have led to a large number of successes. To gain further insight into the biological functions of the differentially expressed genes, gene set enrichment analysis and network-based meta-analysis can be performed by our season scientists, supported by our innovative proprietary bioinformatics solutions. The discovery of potential biomarkers may lead to future practical clinical use.

RNA Sequencing (RNA-seq) for Biomarker Discovery Service 2

RNA-seq solutions at Creative Biolabs, including RNA exome sequencing, total RNA-seq, mRNA-seq, micro RNA-seq, long non-coding RNA sequencing (lncRNA-seq), and circular RNA sequencing (circRNA-seq). All our RNA-Sequencing solutions support novel biomarker discovery and translational research.

Our Portfolio Offers

Measurement of the gene transcript expression
Detection of known, novel gene fusions
Detection of known, novel single nucleotide variants (SNVs)
Identify expression associations
Identify outliers within cohorts
Integrate RNA-seq data with other data, like Gene Expression Microarray, quantitative PCR (qPCR).

By leveraging the wealth of information that we have on RNA-seq for biomarker discovery, Creative Biolabs is pleased to help our clients with their biomarker development projects. For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

Shigemizu, D.; et al. Identification of potential blood biomarkers for early diagnosis of Alzheimer's disease through RNA sequencing analysis. Alzheimer's research & therapy. 2020, 12(1):1-2.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION